I have watch post after post and finally feel the need to clarify some things...I feel like there are a lot of people who keep referring to dumping of shares and a failed alpha and other non-sense statements with no backing.
1) Yesterday, a single buyer picked up ~400k shares and basically purchased anything between 18-20 cents. There was no "dump".. those shares for sale... were listed for some time (... such small volumes being traded). The massive trade/news release sparked turnover across the day.
2) IMPORTANT. those who haven't gone to graduate school or may not understand the complex relationship between university laboratories, Industry (i.e. companies willing to license) and patent-law need try and relax for a minute. Yes, there is some pressure to get a beta released given form 2a and I do believe that will be coming, however, let us consider for a second what is going on. Two products developed side by side. First of all, we should start by considering UFL, not Cannabix. Think about things from UFL's perspective. Yost lab developed the FAIMS-MS technology over YEARS. Inside the lab, the return of a highly trained (e.g. previous graduate school and military research in explosives) Dr. Boock for his PhD, involved targeting THC and other compounds that would be of interest with regards to detection purposes. Of interest with regards to the eventual development of a device that could be used roadside by law enforcement (AND MILITARY). Let me make something clear... Boock and his supervisor, Yost, are the top of the top in this field. If they don't have a product, no on will (even University of Washington is questionable IMHO based on the science). They have a single graduate student working on that technology and their is no industry contract yet - they are far behind). UFL develop a product in the lab, again, over a LONG period of time. Listen closely... the science... the hard part... it is DONE. That patent and all of the research behind it is YEARS of work. IT WORKS. This was hands down the biggest hurdle. Whether Cannabix was in the right time or place to scored this deal, who cares, they did. UFL CANNOT MARKET the technology and develop a marijuana breathalyzer alone, they represent the University and technically the science is the property of the University. They need a licensing contract in order to do so. Enter Cannabix. Cannabix realizes that the Alpha product needs tweaking to become more sensitive. I spoke to management in the past month... they have generated considerable know-how and overlapping IP as a result of their relationship with UFL, and alas, Alpha is not dead. MOST importantly, these guys are working with UFL, not alone. They are not going to go broadcasting to the world, every step of product development they make. They did that too prematurely with alpha and shares tanked because of it. Lesson learned. The news release, was great, it lets shareholders know these guys are a) still working b) not ignoring us c) politics... grants... a big deal... share price upon successful product development will be to the moon, so dilution is not overly worrisome. d) success with Breathtec = success with Cannabix, and look at the amount of time they JUST spent getting the website going... good sign. e) they finally hired on Dr. Boock... again, not necessary if product development was taking off. As I mentioned in a previous post, he has been working with them for some time now (if LinkedIn is correct... May). NOW they hire? This is good.
That's just MHO and DD. I have gone through these processes myself and understand the fragile nature of the relationship with industry and the industry companies obligations to respect the privacy of the technology being developed at UFL. Stay patient friends, this will work out.
